Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Dreher who wrote (232)	10/11/1998 5:00:00 PM
From: Steven Rachbach	Read Replies (1) \| Respond to of 1127

I asked an Oncologist acquaintance of mine to review the literature on MPIF and give an opinion as to its clinical use. MPIF is the first HGSI drug to complete Phase I trials and it shields blood cells from the deleterious effects of chemotherapy. He said that there are already other drugs (colony stimulating factors) that are currently available to ameliorate this problem. He feels that if MPIF makes it to market, it could be used by a relatively small sub-set of cancer patients who need intense and/or frequent chemotherapy. I am somewhat disappointed by his assessment because I thought it that MPIF had a bigger target patient population.